We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$209B
$95.8M 3.37%
416,560
-191,658
-32% -$44.2M
ILMN icon
2
Illumina
ILMN
$31B
$95.3M 3.35%
264,703
-24,221
-8% -$7.72M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$77.4B
$86.7M 3.05%
179,385
-28,003
-14% -$15.1M
JNJ icon
4
Johnson & Johnson
JNJ
$617B
$86.1M 3.02%
546,805
– –
GILD icon
5
Gilead Sciences
GILD
$163B
$81.9M 2.88%
1,405,371
-238,312
-14% -$14.4M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$78.4M 2.76%
501,942
+235,151
+88% +$30.2M
UNH icon
7
UnitedHealth
UNH
$383B
$76.9M 2.7%
219,185
+33,450
+18% +$11.2M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$122B
$72.2M 2.54%
305,310
-96,050
-24% -$22M
ABBV icon
9
AbbVie
ABBV
$455B
$66.4M 2.33%
619,759
-254,961
-29% -$24.5M
MDT icon
10
Medtronic
MDT
$110B
$62.7M 2.2%
534,914
– –
BMY icon
11
Bristol-Myers Squibb
BMY
$132B
$61.4M 2.16%
989,908
+44,768
+5% +$2.75M
BIIB icon
12
Biogen
BIIB
$30.7B
$60.4M 2.12%
246,844
+33,091
+15% +$8.54M
TMO icon
13
Thermo Fisher Scientific
TMO
$214B
$59.4M 2.09%
127,553
+98,092
+333% +$46M
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
$51.4M 1.81%
293,619
-43,585
-13% -$8.13M
DHR icon
15
Danaher
DHR
$138B
$48.8M 1.72%
247,980
+171,764
+225% +$34.4M
ABT icon
16
Abbott
ABT
$183B
$47.2M 1.66%
431,145
+61,572
+17% +$6.69M
MRK icon
17
Merck
MRK
$321B
$45.9M 1.61%
587,826
-519,602
-47% -$39.7M
LLY icon
18
Eli Lilly
LLY
$1.03T
$40.1M 1.41%
237,537
+59,900
+34% +$8.94M
SYK icon
19
Stryker
SYK
$133B
$37.6M 1.32%
153,330
-4,500
-3% -$1.02M
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.64B
$35.2M 1.24%
206,487
– –
HZNP
21
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$34M 1.2%
465,016
-138,668
-23% -$10.3M
HUM icon
22
Humana
HUM
$44B
$34M 1.19%
82,807
-3,200
-4% -$1.33M
ZBH icon
23
Zimmer Biomet
ZBH
$18.4B
$33M 1.16%
220,434
+22,739
+12% +$3.21M
BDX icon
24
Becton Dickinson
BDX
$45.6B
$33M 1.16%
135,016
– –
HCA icon
25
HCA Healthcare
HCA
$85.7B
$28.8M 1.01%
175,097
+93,164
+114% +$13.6M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.